Piecing the Puzzle Together in the Diagnosis and Management of PF-ILD
October 30, 2020
October 30, 2021
Scroll to the Bottom of this Information to Begin this Course
This activity is provided by Paradigm Medical Communications, LLC.
This activity is supported by an educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.
- Physicians — maximum of 1.00 AMA PRA Category 1 Credit(s)™
All other health care professionals completing this course will be issued a statement of participation.
This activity has been designed to meet the educational needs of pulmonologists, radiologists, and pathologists. It may also be of benefit to primary care physicians, PAs, nurse practitioners, nurses, pharmacists, fellows, residents, and other healthcare professionals who care for patients with chronic, progressive fibrosing lung disease (PF-ILD).
Interstitial lung disease (ILD) can be progressive and severely debilitating. Clinicians need to understand the key diagnostic features of ILD and be able to distinguish among different types, particularly those associated with chronic fibrosis and a progressive phenotype, including inflammatory connective-tissue diseases, idiopathic nonspecific interstitial pneumonia (iNSIP), chronic hypersensitivity pneumonitis (HP), and unclassified ILD, which can lead to increased morbidity and mortality. Lack of knowledge regarding CF-ILD with a progressive phenotype, as well as deficits in understanding of disease management, available recommendations, and recent clinical research, are significant barriers to improving outcomes and quality of life for patients. The goal of this activity is to improve recognition and differential diagnosis of ILD subtypes at risk of chronic fibrosis, and to improve management of these patients through integration of traditional and newer therapy options into routine practice.
Upon completion of this activity, participants should be better able to:
- Distinguish among PF-ILD subtypes and the pathophysiology associated with increased risk of progression
- Identify patients with PF-ILD at increased risk of progression who should be closely monitored
- Evaluate evidence from recent and ongoing clinical trials for its impact on the management of PF-ILD
Sonye Danoff, MD, PhD (Chair)
Associate Professor of Medicine
Division of Pulmonary and Critical Care Medicine
Co-Director, Johns Hopkins ILD/PF Program
Associate Director, Myositis Center
Johns Hopkins University School of Medicine
Robert Hallowell, MD
Assistant Professor of Medicine, Harvard Medical School
Pulmonary Clinic Director
Division of Pulmonary, Critical Care and Sleep Medicine
Massachusetts General Hospital
Stephen Hobbs, MD, FSCCT
Associate Professor of Radiology and Medicine
Vice-Chair, Radiology Informatics and Integrated Clinical Operations
Chief, Division of Cardiovascular and Thoracic Radiology
Medical Director, UK HealthCare Imaging Informatics
University of Kentucky
Paradigm Medical Communications, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physician Credit Designation Statement
Paradigm Medical Communications, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
PA Continuing Education
PAs may claim a maximum of 1.0 Category 1 credit for completing this activity. NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society.
Nurse Practitioner Continuing Education
The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Individuals are responsible for checking with the AANPCP for further guidelines.
Disclosures of Conflicts of Interest
In accordance with ACCME requirements on disclosure, faculty and contributors are asked to disclose any relationships with commercial interests associated with the area of medicine featured in the activity. These relationships are described below. Any potential conflicts have been resolved.
Sonye Danoff, MD, PhD
- Consulting Fees: Boehringer Ingelheim Pharmaceuticals, Inc
- Grant/Research Support: Boehringer Ingelheim Pharmaceuticals, Inc; Bristol-Myers Squibb Company; Genentech, Inc.
Robert Hallowell, MD has no financial relationships to disclose.
Stephen Hobbs, MD, FSCCT
- Royalty: Elsevier; Wolters Kluwer NV
Paradigm Medical Communications, LLC staff members have no financial relationships to disclose.
Independent peer, resident/fellow and patient reviewers have no financial relationships to disclose.
Instructions for Participation and Credit
- Follow instructions to register or log in with your professional information and complete the pre-activity assessment
- View the online activity in its entirety
- Complete and submit the online posttest and evaluation. You must answer 70% of the posttest questions correctly to earn credit. You will have unlimited opportunities to successfully complete the posttest
For questions regarding CME credit, contact the Paradigm CME Department at (845) 398-5949 or firstname.lastname@example.org.
There is no fee required for participation in this activity.
Course Viewing Requirements
This certified CME activity is designed using HTML5 web components. As you navigate the video using the supplied controls, the slides will sync to the speaker.
Supported Browsers (Desktop/Mobile)
Chrome 45+, Firefox 40+, Edge, Edge Chromium, Safari 8+, Opera 31+
This activity may contain PDF documents. Most current browsers support viewing of PDFs natively, but you may also download a free version of Adobe Acrobat Reader here: http://get.adobe.com/reader
Technical Support: If you have any technical problems or playback issues email us at email@example.com.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not approved by the FDA.
This CME activity represents the views and opinions of the individual faculty, and does not constitute the opinion or endorsement of, or promotion by, Paradigm Medical Communications, LLC. Reasonable efforts have been taken to present educational subject matter in a balanced, unbiased fashion, and in compliance with regulatory requirements. However, each activity participant must always use his or her own personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses.
If included, signed statements of informed consent granting permission for publication have been obtained for all photographs and videos in which an individual can be identified.
As an ACCME-accredited provider, Paradigm Medical Communications, LLC’s activities must include a balanced view of therapeutic options. Use of generic names contributes to this impartiality. The use of trade names should not be viewed as an endorsement of specific products by Paradigm Medical Communications, LLC.
If you have any questions or comments, please email us at firstname.lastname@example.org.